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Routine influenza vaccination for healthy children—old
concept, new technologies
Annual vaccination against infection with influenza virus
types A and B is strongly recommended for all adults over
the age of 65 years and for persons of all ages, who are at
risk for influenza induced mortality or the development of
serious complications after influenza infection (chronic
cardiac, pulmonary, metabolic, renal or immunological
disorders, residence in institutional care facilities).1 Vacci-
nation is also recommended for children who receive long
term salicylate therapy, to reduce the risk of Reye
syndrome, which occasionally occurs during convalescence
from influenza and varicella infection and shows a strong
correlation with the use of salicylates.2
The absolute number of children at risk for complica-
tions of influenza is small. For them, inactivated purified
surface antigen (subunit) or detergent disrupted (split)
influenza vaccines are available to be administered every
year. Whole virus vaccines, which can be used in adults, are
not recommended for children because of a higher
incidence of vaccine induced systemic reactions,3 such as
transient fever. Previously unvaccinated children less than
9 years of age should receive two doses of half the adult
dose (currently 7.5 µg haemagglutinin per vaccine compo-
nent) at least one month apart to guarantee a satisfactory
antibody response.4 Clinical trials such as the one by
Gonzalez et al reported in this issue of the journal5 and
others6–10 show that this policy is safe in those vulnerable
young individuals.
Healthy children are currently not a target for routine
influenza vaccination although there are at least two good
reasons to support such a policy. Firstly, an infected child
typically sheds high amounts of virus up to two weeks,
while virus shedding in an adult lasts usually only a few
days and produces low titres.11 As a consequence, the epi-
demic curve in preschool and schoolchildren precedes the
overall community peak, and children introduce influenza
epidemics into households and the entire community.12–14
One may expect, and it has even been shown,15 that an
eVective mass vaccination in children would significantly
reduce the overall impact of influenza on the community
and particularly mortality and morbidity in the elderly.
Secondly, influenza illness in children themselves, particu-
larly in infants, is not as innocent as is usually perceived.
The real impact of influenza is confounded by the
co-circulation of viruses like respiratory syncytial virus
(RSV), adenoviruses (AV), or parainfluenza viruses (PIV).
Moreover, an influenza infection in young children can
clinically manifest itself as lower respiratory tract infection,
febrile convulsions, myositis, myocarditis, or pericarditis,
and may be complicated by bacterial superinfections such
as otitis media,16 17 bacterial pneumonia, sepsis, or the toxic
shock syndrome. Influenza is not often recognised as a
cause of these serious clinical conditions.
Two recent studies involving large numbers of observa-
tions corrected for such confounders, revealed the surpris-
ingly high influenza associated morbidity in healthy young
children. Maletic-Neuzil et al showed that the rate of hos-
pitalisations attributable to influenza in infants younger
than 6 months of age was similar to that for adults at high
risk for influenza (104 excess cases per 10 000).18 The rate
of hospitalisation decreased considerably with age but was
increased in all age groups up to 15 years of age. For every
100 children, an annual average of six to 15 outpatient
visits and three to nine courses of antibiotics were attribut-
able to influenza. Izurieta et al found highly increased hos-
pitalisation rates in previously healthy children younger
than two years of age.19 The authors conclude therefore
that routine influenza vaccination should be considered for
all infants and young children.
The concept of a general influenza vaccination pro-
gramme in children meets important logistic, financial, and
other obstacles. National health authorities may be
reluctant to add another entity to the existing crowded
childhood immunisation scheme against a variety of viral
and bacterial diseases, which is certainly diYcult enough to
maintain. The use of the currently available inactivated
vaccine types would mean no less than one or two
additional intramuscular injections every year. In Japan,
such a policy failed. In 1976, obligatory national annual
influenza vaccination was introduced for children of 3 to 15
years. Concerns about serious vaccine reactions, inappro-
priate scientific evaluation and resulting doubts about vac-
cine eYcacy, and public campaigns led to a weakening of
the obligatory nature of the vaccination programme in
1987. Since then, parents have been allowed to refuse
influenza immunisation for their children, and vaccination
rates have decreased sharply in the target group.20 21
Following the Japanese experience, most health authorities
would agree that mass vaccination with the current
influenza vaccine types is not a feasible option.
As a possible alternative, a live, attenuated, cold adapted
vaccine has been developed, which can be administered
intranasally by spray, thus avoiding parenteral injection and
providing higher acceptability in children. It has been
extensively studied in the USA for over 30 years but is not
yet licensed. Its basic concept is the attenuation of the Ann
Arbor master strains by repeated passage on chicken eggs
under decreasing temperature conditions. The final
variants can no longer replicate at human core body
temperature and grow only in the mucous membrane of
the upper respiratory tract where temperatures do not
exceed 32–33°C. Many thousands of doses have been given
in the USA under experimental conditions without serious
concerns about adverse events: local and systemic
reactions were mild and transitory, and regarded as
acceptable. No vaccine induced inflammation of the lower
respiratory tract was seen, and the vaccine appeared to be
reproducibly attenuated, genetically stable, and non-
transmissible.22 A large placebo controlled study in
children 15 to 71 months old showed a vaccine eYcacy of
93% against culture confirmed influenza and, most
interestingly, a 30% reduction of febrile otitis media.23 A
similar vaccine eYcacy was found in another recent trial.24
In comparative studies, eYcacy of the live vaccine appeared
to be similar to that of an inactivated vaccine in all age
groups.25 26
There are also theoretical, though serious, concerns
about the use of living influenza particles in humans. These
include the possibility of co-infection with human or,
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worse, non-human wild type virus and consecutive hazard-
ous reassortment, and the transmission of vaccine virus to
other species.27 28
Another alternative, which combines the safety of the
inactivated vaccine and the convenience of intranasal
administration, is liposomal influenza vaccine. A liposome
is a small suspended sphere (diameter <200 nm) consisting
of a lipid bilayer and serving as vehicle for solubilised viral
proteins.29 Liposomal influenza vaccine for intramuscular
administration30 has already been licensed in some
European countries for adults, and it may also be used for
children at risk.31 Currently, an intranasal formulation is
under study, which shows promising preliminary results in
adults.32 More data, in particular from eYcacy studies, are
needed for a sound clinical assessment. Other vaccine
delivery systems, for example ISCOM,33 34 are candidates
for suitable mucosal influenza vaccines.
Another potential advantage of these vaccine delivery
systems, in addition to their easier mode of administration
(compared to current inactivated vaccines) and probable
greater safety (compared to live vaccine), lies in the poten-
tial to include other immunogenic proteins from influenza
C, respiratory syncytial virus, adenovirus, and parainflu-
enza virus as well, in order to create broad prophylaxis
against the predominant viral causes of serious respiratory
disease in childhood. The next decade will show whether
such an option is feasible.
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